These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18590003)

  • 1. [Pharmacogenetic contribution to individualized treatment. Severe adverse effects can be avoided].
    Eliasson E
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1644-5. PubMed ID: 18590003
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenetics of drug hypersensitivity.
    Phillips EJ; Mallal SA
    Pharmacogenomics; 2010 Jul; 11(7):973-87. PubMed ID: 20602616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01.
    Sousa-Pinto B; Pinto-Ramos J; Correia C; Gonçalves-Costa G; Gomes L; Gil-Mata S; Araújo L; Delgado L
    J Allergy Clin Immunol; 2015 Oct; 136(4):1092-4.e3. PubMed ID: 25934581
    [No Abstract]   [Full Text] [Related]  

  • 4. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.
    Nolan D
    Crit Rev Clin Lab Sci; 2009; 46(3):153-65. PubMed ID: 19514905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future.
    Alfirevic A; Pirmohamed M
    Pharmacogenomics; 2010 Apr; 11(4):497-9. PubMed ID: 20350129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics testing for type B adverse drug reactions to anti-infective drugs: the example of hypersensitivity to abacavir.
    Agundez JA; Esguevillas G; Amo G; Garcia-Martin E
    Recent Pat Antiinfect Drug Discov; 2014; 9(2):151. PubMed ID: 25891395
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
    Phillips EJ
    Clin Infect Dis; 2006 Jul; 43(1):103-5. PubMed ID: 16758425
    [No Abstract]   [Full Text] [Related]  

  • 9. Abacavir hypersensitivity reaction predicted by genetic test.
    AIDS Treat News; 2004 Mar; (399):6. PubMed ID: 15199868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA alleles and drug hypersensitivity reactions.
    Profaizer T; Eckels D
    Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.
    Ingelman-Sundberg M
    N Engl J Med; 2008 Feb; 358(6):637-9. PubMed ID: 18256400
    [No Abstract]   [Full Text] [Related]  

  • 12. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.
    Hughes S; Hughes A; Brothers C; Spreen W; Thorborn D;
    Pharm Stat; 2008; 7(2):121-9. PubMed ID: 17534855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.
    Hughes AR; Spreen WR; Mosteller M; Warren LL; Lai EH; Brothers CH; Cox C; Nelsen AJ; Hughes S; Thorborn DE; Stancil B; Hetherington SV; Burns DK; Roses AD
    Pharmacogenomics J; 2008 Dec; 8(6):365-74. PubMed ID: 18332899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human leukocyte antigens and drug hypersensitivity.
    Chung WH; Hung SI; Chen YT
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
    Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
    Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.
    Nelson MR; Bacanu SA; Mosteller M; Li L; Bowman CE; Roses AD; Lai EH; Ehm MG
    Pharmacogenomics J; 2009 Feb; 9(1):23-33. PubMed ID: 18301416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic approaches to the prediction of drug response.
    Vesell ES
    NIDA Res Monogr; 1986; 66():25-40. PubMed ID: 3106816
    [No Abstract]   [Full Text] [Related]  

  • 18. Abacavir hypersensitivity reaction.
    AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
    [No Abstract]   [Full Text] [Related]  

  • 19. Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.